Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma

Liang, Linjun1,2; Wang, Xiaoyan2; Huang, Shuying2; Chen, Yanwei3; Zhang, Peng1; Li, Liang4; Cui, Yong2

2023-03-01

10.3389/fimmu.2023.1046771

FRONTIERS IN IMMUNOLOGY   影响因子和分区

1664-3224

Hepatocellular carcinoma (HCC) is a high-incidence malignant tumor worldwide and lacks effective treatment options. Targeted drugs are the preferred recommendations for the systemic treatment of hepatocellular carcinoma. Immunotherapy is a breakthrough in the systemic treatment of malignant tumors, including HCC. However, either targeted therapy or immunotherapy alone is inefficient and has limited survival benefits on part of HCC patients. Investigations have proved that tyrosine kinase inhibitors (TKIs) have regulatory effects on the tumor microenvironment and immune response, which are potential sensitizers for immunotherapy. Herein, a combination therapy using TKIs and immunotherapy has been explored and demonstrated to improve the effectiveness of treatment. As an effective immunotherapy, adoptive T cell therapy in solid tumors is required to improve tumor infiltration and killing activity which can be possibly achieved by combination with TKIs.

hepatocellular carcinoma tyrosine kinase inhibitors adoptive T cell therapy immunotherapy combination therapy

SCI

英语

通讯

Immunology

Immunology

WOS:000948786500001

FRONTIERS MEDIA SA

Web of Science

1.Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China
2.Shenzhen Qianhai Shekou Free Trade Zone Hosp, Dept Oncol, Shenzhen, Guangdong, Peoples R China
3.Fourth Mil Med Univ, Dept Pulm Crit Care Med, Tangdu Hosp, Xian, Peoples R China
4.Southern Univ Sci & Technol, Sch Med, Shenzhen, Guangdong, Peoples R China

Liang, Linjun,Wang, Xiaoyan,Huang, Shuying,et al. Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma[J]. FRONTIERS IN IMMUNOLOGY,2023,14.

Liang, Linjun.,Wang, Xiaoyan.,Huang, Shuying.,Chen, Yanwei.,Zhang, Peng.,...&Cui, Yong.(2023).Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma.FRONTIERS IN IMMUNOLOGY,14.

Liang, Linjun,et al."Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma".FRONTIERS IN IMMUNOLOGY 14(2023).